RATIONALE-309: Updated progresssion -free survival from a phase 3 double-blind trail of tislelizumab versus placebo, plus chemotherapy, as first -line treatment for recurrent/metastatic nasopharyngeal cancer.

被引：0
|
作者：
Zhang, Li
Yang, Yunpeng
Pan, Jian-Ji
Chen, Xiaozhong
Sun, Yan
Wang, Hui
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 36期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)
    Yang, Yunpeng
    Pan, Jianji
    Wang, Hui
    Zhao, Yuanyuan
    Qu, Shenhong
    Chen, Nianyong
    Chen, Xiaozhong
    Sun, Yan
    He, Xiaohui
    Hu, Chaosu
    Lin, Lizhu
    Yu, Qitao
    Wang, Siyang
    Wang, Guihua
    Lei, Feng
    Wen, Jiyu
    Yang, Kunyu
    Lin, Zhixiong
    Guo, Ye
    Chen, Shaoqing
    Huang, Xiaoming
    Wu, Yanjie
    Liang, Liang
    Chen, Chenqi
    Bai, Fan
    Ma, Xiaopeng
    Zhang, Yun
    Leaw, Shiangjiin
    Zhang, Li
    Fang, Wenfeng
    CANCER CELL, 2023, 41 (06) : 1061 - +
  • [2] RATIONALE 309: A randomized, global, double-blind, phase III trial of tislelizumab (TIS) vs placebo, plus gemcitabine plus cisplatin (GP), as first-line treatment for recurrent/metastatic nasopharyngeal cancer (RM-NPC)
    Yang, Y.
    Pan, J.
    Wang, H.
    Qu, S.
    Chen, N.
    Chen, X.
    Sun, Y.
    He, X.
    Hu, C.
    Lin, L.
    Yu, Q.
    Wang, S.
    Wang, G.
    Lei, F.
    Wen, J.
    Yang, K.
    Lin, Z.
    Wu, Y.
    Fang, W.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S1430 - S1430
  • [3] Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as fi rst-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study
    Fang, W. F.
    Pan, J.
    Wang, H.
    Qu, S.
    Chen, N.
    Chen, X.
    Sun, Y.
    He, X.
    Hu, C.
    Lin, L.
    Yen, C. J.
    Wu, Y.
    Yuan, S.
    Chen, C.
    Yang, Y.
    Lean, S.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S1554 - S1555
  • [4] RATIONALE-306: Randomized, global, placebo-controlled, double-blind phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC)
    Yoon, H.
    Kato, K.
    Raymond, E.
    Hubner, R.
    Shu, Y.
    Pan, Y.
    Jiang, Y.
    Zhang, J.
    Park, S.
    Kojima, T.
    Lin, C.
    Gotovkin, E.
    Wyrwicz, L.
    Ishihara, R.
    Li, L.
    Tao, A.
    Shi, J.
    Wang, L.
    Xu, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S375 - S375
  • [5] KEYNOTE-826: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
    Shapira-Frommer, Ronnie
    Alexandre, Jerome
    Monk, Bradley
    Fehm, Tanja N.
    Colombo, Nicoletta
    Caceres, Maria V.
    Hasegawa, Kosei
    Dubot, Coraline
    Li, Jerry Jing
    Stein, Karen
    Keefe, Stephen Michael
    Tewari, Krishnansu Sujata
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
    Qiu, Miao-Zhen
    Oh, Do-Youn
    Kato, Ken
    Arkenau, Tobias
    Tabernero, Josep
    Correa, Marcia Cruz
    Zimina, Anastasia, V
    Bai, Yuxian
    Shi, Jianhua
    Lee, Keun-Wook
    Wang, Jufeng
    Poddubskaya, Elena
    Pan, Hongming
    Rha, Sun Young
    Zhang, Ruixing
    Hirano, Hidekazu
    Spigel, David
    Yamaguchi, Kensei
    Chao, Yee
    Wyrwicz, Lucjan
    Disel, Umut
    Cid, Roberto Pazo
    Fornaro, Lorenzo
    Evesque, Ludovic
    Wang, Hongwei
    Xu, Yaling
    Li, Jiang
    Sheng, Tao
    Yang, Silu
    Li, Liyun
    Moehler, Markus
    Xu, Rui-Hua
    BMJ-BRITISH MEDICAL JOURNAL, 2024, 385
  • [7] KEYNOTE-826: FINAL OVERALL SURVIVAL RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF PEMBROLIZUMAB plus CHEMOTHERAPY VS PLACEBO plus CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER
    Monk, Bradley J.
    Colombo, Nicoletta
    Tewari, Krishnansu Sujata
    Dubot, Coraline
    Caceres, M. Valeria
    Hasegawa, Kosei
    Shapira-Frommer, Ronnie
    Salman, Pamela
    Yanez, Eduardo
    Gumus, Mahmut
    De Mendoza, Mivael Olivera Hurtado
    Samouelian, Vanessa
    Castonguay, Vincent
    Arkhipov, Alexander
    Tekin, Cumhur
    Li, Kan
    Keefe, Stephen Michael
    Lorusso, Domenica
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A420 - A420
  • [8] KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer
    Monk, Bradley J.
    Colombo, Nicoletta
    Tewari, Krishnansu Sujata
    Dubot, Coraline
    Caceres, M. Valeria
    Hasegawa, Kosei
    Shapira-Frommer, Ronnie
    Salman, Pamela
    Yanez, Eduardo
    Gumus, Mahmut
    de Mendoza, Mivael Olivera Hurtado
    Samouelian, Vanessa
    Castonguay, Vincent
    Arkhipov, Alexander
    Tekin, Cumhur
    Li, Kan
    Keefe, Stephen Michael
    Lorusso, Domenica
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Patient-Reported Outcomes from the Phase 3 Randomized, Double-Blind, KEYNOTE-826 Trial of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer
    Monk, Bradley
    Tewari, Krishnansu
    Dubot, Coraline
    Caceres, M. Valeria
    Hasegawa, Kosei
    Shapira-Frommer, Ronnie
    Salman, Pamela
    Yanez, Eduardo
    Gumus, Mahmut
    De Mendoza, Mivael Olivera Hurtado
    Samouelian, Vanessa
    Castonguay, Vincent
    Arkhipov, Alexander
    Tekin, Cumhur
    Li, Kan
    Nguyen, Allison Martin
    Monberg, Matthew
    Colombo, Nicoletta
    Lorusso, Domenica
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S18 - S18
  • [10] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
    Xu, Jianming
    Kato, Ken
    Raymond, Eric
    Hubner, Richard A.
    Shu, Yongqian
    Pan, Yueyin
    Park, Sook Ryun
    Ping, Lu
    Jiang, Yi
    Zhang, Jingdong
    Wu, Xiaohong
    Yao, Yuanhu
    Shen, Lin
    Kojima, Takashi
    Gotovkin, Evgeny
    Ishihara, Ryu
    Wyrwicz, Lucjan
    Van Cutsem, Eric
    Jimenez-Fonseca, Paula
    Lin, Chen -Yuan
    Wang, Lei
    Shi, Jingwen
    Li, Liyun
    Yoon, Harry H.
    LANCET ONCOLOGY, 2023, 24 (05): : 483 - 495
12345